144 related articles for article (PubMed ID: 1686817)
21. Ipsapirone challenge in aggressive men shows an inverse correlation between 5-HT1A receptor function and aggression.
Cleare AJ; Bond AJ
Psychopharmacology (Berl); 2000 Mar; 148(4):344-9. PubMed ID: 10928305
[TBL] [Abstract][Full Text] [Related]
22. Smoking modulates neuroendocrine responses to ipsapirone in patients with panic disorder.
Broocks A; Bandelow B; Koch K; Bartmann U; Kinkelbur J; Schweiger U; Hohagen F; Hajak G
Neuropsychopharmacology; 2002 Aug; 27(2):270-8. PubMed ID: 12093600
[TBL] [Abstract][Full Text] [Related]
23. Noradrenergic function in obsessive-compulsive disorder: behavioral and neuroendocrine responses to clonidine and comparison to healthy controls.
Hollander E; DeCaria C; Nitescu A; Cooper T; Stover B; Gully R; Klein DF; Liebowitz MR
Psychiatry Res; 1991 May; 37(2):161-77. PubMed ID: 1876628
[TBL] [Abstract][Full Text] [Related]
24. 5-HT1A responsivity in patients with panic disorder before and after treatment with aerobic exercise, clomipramine or placebo.
Broocks A; Meyer T; Opitz M; Bartmann U; Hillmer-Vogel U; George A; Pekrun G; Wedekind D; Rüther E; Bandelow B
Eur Neuropsychopharmacol; 2003 May; 13(3):153-64. PubMed ID: 12729940
[TBL] [Abstract][Full Text] [Related]
25. The serotonin hypothesis of obsessive compulsive disorder.
Barr LC; Goodman WK; Price LH
Int Clin Psychopharmacol; 1993 Nov; 8 Suppl 2():79-82. PubMed ID: 8201248
[TBL] [Abstract][Full Text] [Related]
26. Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine.
Goodman WK; Price LH; Delgado PL; Palumbo J; Krystal JH; Nagy LM; Rasmussen SA; Heninger GR; Charney DS
Arch Gen Psychiatry; 1990 Jun; 47(6):577-85. PubMed ID: 2112374
[TBL] [Abstract][Full Text] [Related]
27. Serotonergic responsivity in obsessive-compulsive disorder. Comparison of patients and healthy controls.
Zohar J; Mueller EA; Insel TR; Zohar-Kadouch RC; Murphy DL
Arch Gen Psychiatry; 1987 Nov; 44(11):946-51. PubMed ID: 3675134
[TBL] [Abstract][Full Text] [Related]
28. Effect of aerobic exercise on behavioral and neuroendocrine responses to meta-chlorophenylpiperazine and to ipsapirone in untrained healthy subjects.
Broocks A; Meyer T; Gleiter CH; Hillmer-Vogel U; George A; Bartmann U; Bandelow B
Psychopharmacology (Berl); 2001 May; 155(3):234-41. PubMed ID: 11432685
[TBL] [Abstract][Full Text] [Related]
29. Neuroendocrine responses to single doses of buspirone in obsessive-compulsive disorder.
Norman TR; Apostolopoulos M; Burrows GD; Judd FK
Int Clin Psychopharmacol; 1994; 9(2):89-94. PubMed ID: 8056999
[TBL] [Abstract][Full Text] [Related]
30. Neuroendocrine and behavioral responses to mCPP in Obsessive-Compulsive Disorder.
Khanna S; John JP; Reddy LP
Psychoneuroendocrinology; 2001 Feb; 26(2):209-23. PubMed ID: 11087965
[TBL] [Abstract][Full Text] [Related]
31. Effect of chronic fluoxetine and WAY-100635 treatment on serotonergic neurotransmission in the frontal cortex.
Dawson LA; Nguyen HQ; Smith DL; Schechter LE
J Psychopharmacol; 2002 Jun; 16(2):145-52. PubMed ID: 12095073
[TBL] [Abstract][Full Text] [Related]
32. Complex effects of age and gender on hypothermic, adrenocorticotrophic hormone and cortisol responses to ipsapirone challenge in normal subjects.
Gelfin Y; Lerer B; Lesch KP; Gorfine M; Allolio B
Psychopharmacology (Berl); 1995 Aug; 120(3):356-64. PubMed ID: 8524984
[TBL] [Abstract][Full Text] [Related]
33. Zolmitriptan (a 5-HT1B/1D receptor agonist with central action) does not increase symptoms in obsessive compulsive disorder.
Boshuisen ML; den Boer JA
Psychopharmacology (Berl); 2000 Sep; 152(1):74-9. PubMed ID: 11041318
[TBL] [Abstract][Full Text] [Related]
34. S 15535, a novel benzodioxopiperazine ligand of serotonin (5-HT)1A receptors: I. Interaction with cloned human (h)5-HT1A, dopamine hD2/hD3 and h alpha2A-adrenergic receptors in relation to modulation of cortical monoamine release and activity in models of potential antidepressant activity.
Millan MJ; Newman-Tancredi A; Rivet JM; Brocco M; Lacroix P; Audinot V; Cistarelli L; Gobert A
J Pharmacol Exp Ther; 1997 Jul; 282(1):132-47. PubMed ID: 9223549
[TBL] [Abstract][Full Text] [Related]
35. Comparison of neuroendocrine and behavioral effects of ipsapirone, a 5-HT1A agonist, in three stress paradigms: immobilization, forced swim and conditioned fear.
Rittenhouse PA; Bakkum EA; O'Connor PA; Carnes M; Bethea CL; van de Kar LD
Brain Res; 1992 May; 580(1-2):205-14. PubMed ID: 1354556
[TBL] [Abstract][Full Text] [Related]
36. Effects of ipsapirone in healthy subjects: a dose-response study.
Kahn RS; Trestman R; Lawlor BA; Gabriel S; Davidson M; Siever L
Psychopharmacology (Berl); 1994 Feb; 114(1):155-60. PubMed ID: 7846198
[TBL] [Abstract][Full Text] [Related]
37. Buspirone induced prolactin responses in obsessive-compulsive disorder (OCD): is OCD a 5-HT2 receptor disorder?
Lucey JV; Butcher G; Clare AW; Dinan TG
Int Clin Psychopharmacol; 1992; 7(1):45-9. PubMed ID: 1624756
[TBL] [Abstract][Full Text] [Related]
38. Lithium and 5-HT1A receptor sensitivity: a neuroendocrine study in healthy volunteers.
Walsh AE; Ware CJ; Cowen PJ
Psychopharmacology (Berl); 1991; 105(4):568-72. PubMed ID: 1663254
[TBL] [Abstract][Full Text] [Related]
39. [Central serotonin receptors and chronic treatment with selective serotonin reuptake inhibitors in the rat: comparative effects of fluoxetine and paroxetine].
Le Poul E; Lima L; Laporte AM; Even C; Doucet E; Fattaccini CM; Laaris N; Hamon M; Lanfumey L
Encephale; 1995; 21(2):123-32. PubMed ID: 7781583
[TBL] [Abstract][Full Text] [Related]
40. Serotonergic function in obsessive-compulsive disorder. Behavioral and neuroendocrine responses to oral m-chlorophenylpiperazine and fenfluramine in patients and healthy volunteers.
Hollander E; DeCaria CM; Nitescu A; Gully R; Suckow RF; Cooper TB; Gorman JM; Klein DF; Liebowitz MR
Arch Gen Psychiatry; 1992 Jan; 49(1):21-8. PubMed ID: 1728249
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
